284 related articles for article (PubMed ID: 32277480)
21. Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells.
Faddaoui A; Sheta R; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Gobeil S; Morin C; Ghani K; Bachvarov D
Cell Cycle; 2017 Apr; 16(7):693-706. PubMed ID: 28278050
[TBL] [Abstract][Full Text] [Related]
22. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
Lin M; Xia B; Qin L; Chen H; Lou G
DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
[TBL] [Abstract][Full Text] [Related]
23. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
24. Knockdown of ribosomal protein S6 suppresses proliferation, migration, and invasion in epithelial ovarian cancer.
Yang X; Xu L; Yang YE; Xiong C; Yu J; Wang Y; Lin Y
J Ovarian Res; 2020 Aug; 13(1):100. PubMed ID: 32862831
[TBL] [Abstract][Full Text] [Related]
25. The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells.
Faddaoui A; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Gobeil S; Morin C; Macdonald E; Vanderhyden B; Bachvarov D
Oncotarget; 2016 Mar; 7(12):14125-42. PubMed ID: 26871602
[TBL] [Abstract][Full Text] [Related]
26. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition.
Parikh A; Lee C; Joseph P; Marchini S; Baccarini A; Kolev V; Romualdi C; Fruscio R; Shah H; Wang F; Mullokandov G; Fishman D; D'Incalci M; Rahaman J; Kalir T; Redline RW; Brown BD; Narla G; DiFeo A
Nat Commun; 2014; 5():2977. PubMed ID: 24394555
[TBL] [Abstract][Full Text] [Related]
27. miR-590-3p Promotes Ovarian Cancer Growth and Metastasis via a Novel FOXA2-Versican Pathway.
Salem M; O'Brien JA; Bernaudo S; Shawer H; Ye G; Brkić J; Amleh A; Vanderhyden BC; Refky B; Yang BB; Krylov SN; Peng C
Cancer Res; 2018 Aug; 78(15):4175-4190. PubMed ID: 29748371
[TBL] [Abstract][Full Text] [Related]
28. CKS2 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in epithelial ovarian cancer.
Xu JH; Wang Y; Xu D
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3225-3234. PubMed ID: 31081074
[TBL] [Abstract][Full Text] [Related]
29. High expression of SLC7A1 in high-grade serous ovarian cancer promotes tumor progression and is involved in MAPK/ERK pathway and EMT.
You S; Han X; Xu Y; Sui L; Song K; Yao Q
Cancer Med; 2024 May; 13(10):e7217. PubMed ID: 38752472
[TBL] [Abstract][Full Text] [Related]
30. LINC00968 accelerates the progression of epithelial ovarian cancer via mediating the cell cycle progression.
Yao N; Sun JQ; Yu L; Ma L; Guo BQ
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4642-4649. PubMed ID: 31210289
[TBL] [Abstract][Full Text] [Related]
31. Down-regulation of long noncoding RNA DLX6-AS1 defines good prognosis and inhibits proliferation and metastasis in human epithelial ovarian cancer cells via Notch signaling pathway.
Zhao J; Liu HR
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3243-3252. PubMed ID: 31081076
[TBL] [Abstract][Full Text] [Related]
32. The polypeptide GALNT6 Displays Redundant Functions upon Suppression of its Closest Homolog GALNT3 in Mediating Aberrant O-Glycosylation, Associated with Ovarian Cancer Progression.
Sheta R; Bachvarova M; Macdonald E; Gobeil S; Vanderhyden B; Bachvarov D
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31071912
[TBL] [Abstract][Full Text] [Related]
33. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
34. Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome.
Clifford C; Vitkin N; Nersesian S; Reid-Schachter G; Francis JA; Koti M
Am J Reprod Immunol; 2018 Aug; 80(2):e12975. PubMed ID: 29781548
[TBL] [Abstract][Full Text] [Related]
35. Long Non-coding RNA
Yim GW; Kim HJ; Kim LK; Kim SW; Kim S; Nam EJ; Kim YT
Cancer Res Treat; 2017 Jul; 49(3):656-668. PubMed ID: 27737536
[TBL] [Abstract][Full Text] [Related]
36. BRMS1L suppresses ovarian cancer metastasis via inhibition of the β-catenin-wnt pathway.
Cao P; Zhao S; Sun Z; Jiang N; Shang Y; Wang Y; Gu J; Li S
Exp Cell Res; 2018 Oct; 371(1):214-221. PubMed ID: 30118697
[TBL] [Abstract][Full Text] [Related]
37. Long non‑coding RNA CASC2 inhibits progression and predicts favorable prognosis in epithelial ovarian cancer.
Xue Z; Zhu X; Teng Y
Mol Med Rep; 2018 Dec; 18(6):5173-5181. PubMed ID: 30320385
[TBL] [Abstract][Full Text] [Related]
38. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
39. High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer.
Han GH; Yun H; Chung JY; Kim JH; Cho H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36999629
[TBL] [Abstract][Full Text] [Related]
40. SALL4 as an Epithelial-Mesenchymal Transition and Drug Resistance Inducer through the Regulation of c-Myc in Endometrial Cancer.
Liu L; Zhang J; Yang X; Fang C; Xu H; Xi X
PLoS One; 2015; 10(9):e0138515. PubMed ID: 26407074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
